Condition: Psoriasis · Sponsor: Swiss Dermatology Network for Targeted Therapies
The purpose of this study is to evaluate the long-term course of patients with psoriasis and psoriatic-arthritis in systemic treatments such as, methotrexate, cyclosporin A, fumaric acids, acitretin, systemic PUVA, etanercept, infliximab, adalimumab and ustekinumab. A patient will be included at first initiation of the treatment and will remain in the registry for 10 years, regardless of subsequent therapy. The registry will also evaluate safety clinical outcomes and health related quality of life.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Aarau Cantonal Hospital | Aarau, Switzerland | Recruiting |
| Basel University Hospital | Basel, Switzerland | Recruiting |
| Inselspital - Bern University Hospital | Bern, Switzerland | Recruiting |
| Centre Hospitalier Universitaire Vaudois (CHUV) | Lausanne, Switzerland | Recruiting |
| St. Gallen Cantonal Hospital | Sankt Gallen, Switzerland | Recruiting |
| Zurich University Hospital | Zurich, Switzerland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT01706692